LENZ Therapeutics, Inc. (NASDAQ:LENZ) Director Buys $15,000,075.27 in Stock

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Director Ra Capital Management, L.P. bought 998,009 shares of the firm’s stock in a transaction that occurred on Thursday, March 21st. The shares were acquired at an average cost of $15.03 per share, with a total value of $15,000,075.27. Following the purchase, the director now directly owns 3,319,339 shares of the company’s stock, valued at $49,889,665.17. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

LENZ Therapeutics Stock Up 30.3 %

Shares of LENZ Therapeutics stock opened at $21.81 on Thursday. LENZ Therapeutics, Inc. has a 52 week low of $14.07 and a 52 week high of $29.82. The company has a market capitalization of $181.46 million, a price-to-earnings ratio of -1.40 and a beta of 0.20.

Analysts Set New Price Targets

Separately, Piper Sandler started coverage on LENZ Therapeutics in a research note on Wednesday. They set an “overweight” rating and a $28.00 target price for the company.

About LENZ Therapeutics

Graphite Bio Inc is a clinical-stage, next-generation gene editing company focused on therapies to treat or cure serious diseases. Graphite Bio Inc is based in SOUTH SAN FRANCISCO, Calif.